Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2016, Article ID 7510901, 4 pages
http://dx.doi.org/10.1155/2016/7510901
Case Report

A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity

1Department of Hematology and Oncology, Suzuka General Hospital, Yamanohana, Yasuzuka, Suzuka, Mie Prefecture 1275-53, Japan
2Department of Pharmacy, Mie University Hospital, Edobashi 2-174, Tsu, Mie Prefecture 514-8507, Japan
3Department of Hematology and Oncology, Mie University Graduate School of Medicine, Edobashi 2-174, Tsu, Mie Prefecture 514-8507, Japan

Received 9 October 2015; Accepted 20 December 2015

Academic Editor: Raffaele Palmirotta

Copyright © 2016 Keiki Nagaharu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Heidelberger, N. K. Chaudhuri, P. Danneberg et al., “Fluorinated pyrimidines, a new class of tumour-inhibitory compounds,” Nature, vol. 179, no. 4561, pp. 663–666, 1957. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Tsuji, H. Yasui, Y. Onozawa et al., “Modified folfox-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study,” Japanese Journal of Clinical Oncology, vol. 42, no. 8, pp. 686–690, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. C.-C. Liaw, S.-J. Liaw, C.-H. Wang, M.-C. Chiu, and J.-S. Huang, “Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouracil,” Anti-Cancer Drugs, vol. 4, no. 3, pp. 311–315, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. K. H. Yeh and A. L. Cheng, “High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy,” British Journal of Cancer, vol. 75, no. 3, pp. 464–465, 1997. View at Google Scholar · View at Scopus
  5. M. Nobuhiro, G. Takashi, M. Takanori et al., “Risk factors for hyperammonemia during mFOLFOX6 treatment,” Gan To Kagaku Ryoho, vol. 40, no. 4, pp. 483–487, 2013. View at Google Scholar
  6. R. W. Sparidans, T. M. Bosch, M. Jörger, J. H. M. Schellens, and J. H. Beijnen, “Liquid chromatography–tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and β-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 839, no. 1-2, pp. 45–53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. B. P. van Kuilenburg, J. Haasjes, D. J. Richel et al., “Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene,” Clinical Cancer Research, vol. 6, no. 12, pp. 4705–4712, 2000. View at Google Scholar · View at Scopus
  8. Y. Wettergren, G. Carlsson, E. Odin, and B. Gustavsson, “Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy,” Cancer, vol. 118, no. 11, pp. 2935–2943, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Gamelin, M. Boisdron-Celle, V. Guérin-Meyer et al., “Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage,” Journal of Clinical Oncology, vol. 17, no. 4, pp. 1105–1110, 1999. View at Google Scholar · View at Scopus
  10. Y. Nakayama, K. Matsumoto, Y. Inoue et al., “Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs,” Anticancer Research, vol. 26, no. 5, pp. 3983–3988, 2006. View at Google Scholar · View at Scopus
  11. M. H. Kristensen, P. Pedersen, and J. Mejer, “The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracilrelated toxicity in colorectal cancer patients,” Journal of International Medical Research, vol. 38, no. 4, pp. 1313–1323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. B. E. Harris, J. T. Carpenter, and R. B. Diasio, “Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome,” Cancer, vol. 68, no. 3, pp. 499–501, 1991. View at Google Scholar · View at Scopus
  13. Y.-A. Kim, H. C. Chung, H. J. Choi, S. Y. Rha, J. S. Seong, and H.-C. Jeung, “Intermediate dose 5-fluorouracil-induced encephalopathy,” Japanese Journal of Clinical Oncology, vol. 36, no. 1, pp. 55–59, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. L.-H. Li, H. Dong, F. Zhao et al., “The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil,” European Journal of Cancer, vol. 49, no. 7, pp. 1752–1760, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Carlsson, E. Odin, B. Gustavsson, and Y. Wettergren, “Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy,” Cancer Chemotherapy and Pharmacology, vol. 74, no. 4, pp. 757–763, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. S.-R. Kim, C.-H. Park, S. Park, J.-O. Park, J. Lee, and S.-Y. Lee, “Genetic polymorphisms associated with 5-fluorouracil-induced neurotoxicity,” Chemotherapy, vol. 56, no. 4, pp. 313–317, 2010. View at Publisher · View at Google Scholar · View at Scopus